2,6-二氯甲基吡啶盐酸盐 | 55422-79-2

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2,6-二氯甲基吡啶盐酸盐
• 中文别名: 2,6-双氯甲基吡啶盐酸盐
• 英文名称: 2,6-bis(chloromethyl)pyridine hydrochloride
• 英文别名: 2,6-bis(chloromethyl)pyridinium chloride；2,6-dichloromethylpyridine hydrochloride；2,6-Bis(chloromethyl)pyridinium chloride；2,6-bis(chloromethyl)pyridin-1-ium;chloride
• CAS: 55422-79-2
• 化学式: C₇H₇Cl₂N*ClH
• 分子量: 212.506
• InChiKey: FGBGOYAWNBDXCH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.98
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  12.9
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 危险品标志：
  Xn
• 海关编码：
  2933399090
• 包装等级：
  III
• 危险类别：
  8
• 危险性防范说明：
  P261,P264,P270,P271,P280,P302+P352,P304+P340,P305+P351+P338,P310,P330,P332+P313,P362,P403+P233,P405,P501
• 危险品运输编号：
  1759
• 危险性描述：
  H302,H315,H318,H335
• 储存条件：
  室温

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2,6-Bis(chloromethyl)pyridine, HCl
Synonyms: 2,6-Dichloromethyl pyridine hydrochloride

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2,6-Bis(chloromethyl)pyridine, HCl
CAS number: 55422-79-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H8Cl3N
Molecular weight: 212.5

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2,6-二氯甲基吡啶盐酸盐 在 palladium on activated charcoal silver tetrafluoroborate 、 [1,3,5-tris-[3,5-(Me₂N)2-phenyl]benzene][PtCl]3 、 氢气 、 sodium 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 40.0h， 生成 3,22,30,49,57,76-Hexaoxa-82,83,84-triazatetracyclo[76.3.1.124,28.151,55]tetraoctaconta-1(82),24(84),25,27,51,53,55(83),78,80-nonaene
  参考文献：
  名称：

  通过闭环复分解（RCM）进行模板指导的大杂环合成的一般方法

  摘要：

  报道了一种制备大杂环的通用方法，其中使用刚性对称的镀铂的tris-pincer tricationic complex（3）作为模板。该系统使用双烯烃官能化的吡啶配体（1、2），它们选择性地结合到模板的三个铂中心，从而导致烯烃尾部的预组织。通过对这些预先组织的复合体进行处理（4在烯烃复分解反应条件下，烯烃尾部相互连接，提供了几种不同组成和尺寸的大杂环。合成了具有不同取代模式（2,6-和3,5-二取代）和不同烯烃尾基（脂肪族，聚醚和苯乙烯基）的各种吡啶，并将其用于环化反应中，显示了该方法的多样性。发现仅使用2，6-二取代的吡啶导致形成所需的大环，而3，5-二官能化的吡啶仅形成吡啶并环。此外，烯烃尾的长度需要至少为十一个原子（C或O），以便抑制低聚反应，有利于大环的形成。使用第一代[Cl 2（Cy 3 P）2 Ru CHPh]或第二代[Cl 2（Cy 3 P）（IMes）Ru CHPh] Gr

  DOI：

  10.1002/adsc.200404282
• 作为产物：
  描述：

  2,6-二甲基吡啶 在 aluminum (III) chloride 、 sodium tetrahydroborate 、 potassium permanganate 、 氯化亚砜 、 硫酸 、 水 作用下， 以 四氢呋喃 、 甲醇 、 甲苯 为溶剂， 反应 0.58h， 生成 2,6-二氯甲基吡啶盐酸盐
  参考文献：
  名称：

  一种2,6-二氯甲基吡啶盐酸盐的制备方法

  摘要：

  本发明属于有机合成领域，具体涉及一种2,6‑二氯甲基吡啶盐酸盐的制备方法，该方法包括以下步骤：(1)以2,6‑二甲基吡啶为原料，制备2,6‑吡啶二甲酸；(2)2,6‑吡啶二甲酸与甲醇在酸性条件下生成2,6‑吡啶二甲酸二甲酯；(3)2,6‑吡啶二甲酸二甲酯还原为2,6‑吡啶二甲醇；(4)2,6‑吡啶二甲醇与氯化亚砜反应得到目的产物2,6‑二氯甲基吡啶盐酸盐。采用本发明的有益效果是：本发明采用常用的含有吡啶环的化工原料进行乙酰基化反应，反应步骤少，成本低，毒性小，收率高，适于工业化生产。

  公开号：

  CN110818617A

文献信息

• [EN] AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS<br/>[FR] AZOLOPYRIMIDINE POUR LE TRAITEMENT DE TROUBLES LIÉS AU CANCER
  申请人：ARCUS BIOSCIENCES INC

  公开号：WO2018136700A1

  公开（公告）日：2018-07-26

  Compound that is an inhibitor of at least one of the A2A and A2B adenosine receptors, and compositions containing the compound and methods for synthesizing the compound, are described herein. The use of such compound and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine A2A receptor and/or the adenosine A2B receptor.

  本文描述了一种至少抑制A2A和A2B腺苷受体中至少一种的化合物，以及含有该化合物的组合物和合成该化合物的方法。利用这种化合物和组合物治疗各种疾病、紊乱和病况，包括至少部分由腺苷A2A受体和/或腺苷A2B受体介导的癌症和免疫相关紊乱。
• Synthesis and Characterization of PY2- and TPA-Appended Diphenylglycoluril Receptors and Their Bis-CuI Complexes
  作者：Vera S. I. Sprakel、Johannes A. A. W. Elemans、Martin C. Feiters、Baldo Lucchese、Kenneth D. Karlin、Roeland J. M. Nolte

  DOI：10.1002/ejoc.200500865

  日期：2006.5

  A number of metallohosts mimicking dinuclear copper oxygenases have been designed and synthesized. These metallohosts combine a substrate binding site, i.e. the diphenylglycoluril basket receptor, with two types of metal-binding ligands, viz. tri-coordinating bis(2-ethylpyridine)amine (PY2) and tetra-coordinating tris(2-methylpyridine)amine (TPA). The preparation of the bis-Cu I complexes of the ligand

  已经设计并合成了许多模拟双核铜加氧酶的金属宿主。这些金属宿主将底物结合位点（即二苯基甘脲篮式受体）与两种类型的金属结合配体（即。三配位双(2-乙基吡啶)胺(PY2)和四配位三(2-甲基吡啶)胺(TPA)。配体双Cu I配合物的制备
• S,S'-bis(pyridylmethyl)-carbonodithioates
  申请人：Merck & Co., Inc.

  公开号：US03971797A1

  公开（公告）日：1976-07-27

  S,S'-bis(pyridylmethyl)-carbonodithioates and derivatives thereof have utility in the treatment of rheumatoid arthritis. The compound useful in the method of treatment is prepared from known pyridine derivatives and, principally, from pyridoxine and related compounds.

  S，S'-双(吡啶甲基)-碳二硫酸酯及其衍生物在治疗类风湿关节炎方面具有用途。用于治疗的化合物是从已知的吡啶衍生物以及主要来源于吡哆醇和相关化合物制备而成的。
• [EN] 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER<br/>[FR] DÉRIVÉS DE 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)MÉTHYL)PYRIDINE ET DE N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE ET COMPOSÉS ASSOCIÉS EN TANT QU'INHIBITEURS DE PHOSPHOINOSITIDE 3-KINASE (PI3K) DANS LE TRAITEMENT DU CANCER
  申请人：BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA

  公开号：WO2020039097A1

  公开（公告）日：2020-02-27

  2,6-bis(((lH-benzo[d]imidazol-2-yl)thio)methyl)pyridine and N2, N6-dibenzylpyridine-2, 6-dicarboxamide derivatives and related compounds as phosphoinositide 3-kinase (PI3K) inhibitors for treating cancer. The present invention relates to pharmaceutically active 2,6- bis(((lH-benzo[d]imidazol-2-yl)thio)methyl)pyridine, N2,N6- dibenzylpyridine-2, 6-dicarboxamide and N2,N6-bis(3-hydroxyphenyl) pyridine-2, 6-dicarboxamide, as well as to derivatives thereof, and to structurally related compounds. These compounds are phosphoinositide 3-kinase inhibitors (PI3K) and useful in treating or preventing cancerous diseases. The invention further relates methods of manufacturing such compounds as well as to pharmaceutical compositions and formulations comprising such compounds, optionally together with other pharmaceutically active compounds. The invention further relates to a method for determining the activity of PI3Kalpha or PI3Kalpha mutants, which method includes: a) providing a solid phase which is functionalized by immobilization of GST-GRPl-molecules onto the solid phase, b) performing a PI3Kalpha or PI3Kalpha mutant catalyzed enzyme reaction to convert PIP2 to PIP3, c) adding competitor PIP3 carrying a detectable label or reporter molecule, and d) determining enzyme activity based on the amount of PIP3 obtained in step b) which competes with competitor PIP3 for binding to the functionalized solid phase.

  2,6-双(((1H-苯并[d]咪唑-2-基)硫)甲基)吡啶和N2，N6-二苄基吡啶-2,6-二甲酰胺衍生物及相关化合物作为治疗癌症的磷脂酰肌醇3-激酶（PI3K）抑制剂。本发明涉及具有药用活性的2,6-双(((1H-苯并[d]咪唑-2-基)硫)甲基)吡啶，N2，N6-二苄基吡啶-2,6-二甲酰胺和N2，N6-双(3-羟基苯基)吡啶-2,6-二甲酰胺，以及其衍生物和结构相关化合物。这些化合物是磷脂酰肌醇3-激酶抑制剂（PI3K），可用于治疗或预防癌症性疾病。本发明还涉及制造这类化合物的方法，以及包含这类化合物的药物组合物和配方，可选地与其他药用活性化合物一起使用。本发明还涉及一种确定PI3Kalpha或PI3Kalpha突变体活性的方法，该方法包括：a)提供通过将GST-GRPl分子固定在固相上而功能化的固相，b)执行PI3Kalpha或PI3Kalpha突变体催化的酶反应将PIP2转化为PIP3，c)添加携带可检测标签或报告分子的竞争物PIP3，d)根据步骤b)中获得的与竞争物PIP3竞争与功能化固相结合的PIP3的数量确定酶活性。
• Syntheses and crystal structures of Ni(II) complexes with pyridine-based macrocyclic ligands
  作者：Eva Zahradníková、Ivana Císařová、Bohuslav Drahoš

  DOI：10.1016/j.poly.2021.115552

  日期：2022.1

  prepared and thoroughly characterized. Single crystal X-ray structural analysis confirmed that all the complexes have a coordination number of six and their geometries are close to octahedral. In the case of the mononuclear complexes 1 and 2, all the nitrogen atoms of the macrocycle are coordinated, however, in the dinuclear complex 3 with the piperazine-based ligand L3, two nitrogen donor atoms (of the total

  三个基于吡啶的大环配体，两个包含一个吡啶悬臂（L 1和L 2），一个在大环支架中包含哌嗪环（L 3），大环的大小从 12-、14- 增加到 30- L 1 – L 3 的元环被合成和表征。一系列 Ni(II) 与所有这些配体形成复合物，分子式为 [Ni L 1 (CH 3 OH)](ClO 4 ) 2 ( 1 ), [Ni L 2 (CH 3 CN)](ClO 4 )2 ( 2 ) 和 [Ni 2 L 3 (DMF) 2 (CH 3 CN) 2 ](ClO 4 ) 4 ( 3 ) (DMF = N , N-二甲基甲 酰胺) 被制备并彻底表征。单晶X射线结构分析证实，所有配合物的配位数均为6，几何形状接近八面体。在单核配合物1和2的情况下，大环的所有氮原子都配位，然而，在双核配合物3 中，配位体L如图3所示，两个氮供体原子（总共十个）是不配位的。所有配合物的第一配位球都是由溶剂分子完成的。的